Joseph S. Zakrzewski is Chairman at Amarin. Mr. Zakrzewski joined Amarin in January 2010 as Executive Chairman. Mr. Zakrzewski has more than 20 years of industry experience, including significant contributions to Reliant Pharmaceuticals as Chief Operating Officer during the period when Omacor®/Lovaza® was successfully developed, launched, and marketed for reducing very high triglyceride levels, leading to its 2007 acquisition by GlaxoSmithKline. In addition, Mr. Zakrzewski contributed 17 years of service to Eli Lilly & Company in a variety of capacities, including Vice President of Corporate Business Development where he had global responsibility for licensing activities. Mr. Zakrzewski also serves on the Boards of Acceleron Pharma and Insulet Corporation.
Joseph Anderson, Ph.D., joined Amarin as a Non-Executive Director in October 2009. Dr. Anderson is a Partner at Abingworth LLP, an international investment group dedicated to the life sciences and healthcare sectors. He leads private investments in public companies in the U.S. and Europe and manages open-market portfolios of small-cap public equities. He has more than 20 years experience as a Fund Manager and Analyst in the pharmaceutical and bioscience sectors. Dr. Anderson was previously at First State Investments in London, part of the Commonwealth Bank of Australia, where he was Head of Global Healthcare Equities and Portfolio Manager. Prior to this, he was Pharmaceuticals Analyst at investment bank, Dresdner Kleinwort Benson. From 1990–98, Dr. Anderson established and was Head of the Strategy Unit at the Wellcome Trust, one of the world's largest medical foundations. Dr. Anderson is currently a Director of Algeta ASA, a publicly quoted oncology company developing radiopharmaceuticals and a Director of Abingworth BioEquities, an offshore investment fund. He has a Ph.D. in Biochemistry.
Lars Ekman, MD, Ph.D., joined Amarin as a Non-Executive Director in November 2008 and was named Amarin's lead independent director in October 2011. With more than 28-years of experience in the pharmaceutical industry, Dr. Ekman is an Executive Partner of Sofinnova Ventures. He previously served as Co-Founder and Chief Executive Officer of Cebix Inc, and prior to that he was Executive Vice President and President of Global Research and Development of Elan Corporation plc from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at Schwarz Pharma AG from February 1997 to December 2000, and was previously employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer. He serves as Executive Chairman of Sophiris Bio Inc. (formerly Protox Therapeutics) as well as Chairman of Prothena Biosciences. Dr. Ekman also sits on the Board of Directors of Cebix Inc., InterMune, and Ocera Therapeutics. Dr. Ekman is a board certified surgeon with a PhD in experimental biology and has held several clinical and academic positions in the United States and Europe. He obtained his PhD and MD from the University of Gothenburg, Sweden.
Carl L. Gordon, Ph.D., CFA,, joined Amarin as a Non-Executive Director in May 2008. Dr. Gordon is a founding General Partner and Co-Head of Private Equity of OrbiMed Advisors LLC. Dr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.
James Healy, M.D., Ph.D., joined Amarin as a Non-Executive Director in May 2008. Dr. Healy joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was a founding investor and board member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea, and Intermune. He also serves on the boards of directors of several private companies. In the pharmaceutical industry Dr. Healy held positions at Bayer Pharmaceuticals (Miles) and ISTA Pharmaceuticals prior to its initial public offering. He began his private equity career at Sanderling. Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received a Departmental Citation. He received his M.D. from Stanford University's School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation. Dr. Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group.
Jan van Heek joined Amarin as a Non-Executive Director in February 2010. He has more than 30 years in the healthcare industry. He is currently a Principal and Partner at BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint, Mr. van Heek spent more than 18 years at Genzyme Corporation, most recently as Senior Advisor to the CEO and senior management team. Mr. van Heek joined Genzyme in 1991, where as Executive Vice President, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses. Mr. van Heek is currently a board member of PanGenetics BV in the Netherlands and was a board member of and Chairman of the Audit Committee of ViaCell Corporation, a US public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. Between 2007 and 2009, he was Chairman of the Board of BioVex Inc. in Woburn, MA and where he also chaired its Audit and Compensation Committees. Mr. van Heek also served on the board of Zelos Therapeutics, Inc. between 2004 and 2008. Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the US. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.
Patrick O'Sullivan joined Amarin as a Non-Executive Director in December 2011. Mr. O'Sullivan has more than 40 years of pharmaceutical industry experience including more than 30 years as Chief Executive Officer and member of the Board of Directors of the LEO Pharma companies in Ireland and more than 10 years as a member of the Board of Directors of the parent company of the LEO Pharma Group in Denmark. Since 2007 he has been a business consultant to the pharmaceutical industry and he currently serves as a member of the Board of Directors of Warner Chilcott Plc. Mr. O'Sullivan earned Bachelor of Commerce and M.B.A. degrees from University College Dublin. He is a registered pharmacist, a member and honorary fellow of the Pharmaceutical Society of Ireland, and a Knight of the Order of the Dannebrog.
Kristine Peterson joined Amarin as a Non-Executive Director in November 2010. Ms. Peterson has more than 27 years of industry experience. She is currently Chief Executive Officer at Valeritas, Inc., a medical technology company dedicated to the development and commercialization of innovative drug delivery solutions, with its lead product for the treatment of diabetes. Until joining Valeritas, Ms. Peterson was Company Group Chair of Johnson & Johnson's biotech groups. Previously, she was Executive Vice President for J&J's global strategic marketing organization. Prior to J&J, Ms. Peterson was Senior Vice President, Commercial Operations for Biovail Corporation and President for Biovail Pharmaceuticals. Earlier, she spent 20 years with Bristol-Myers Squibb where she held assignments of increasing responsibility in marketing, sales, and general management, including running a cardiovascular/metabolics business unit and a generic division. Ms. Peterson is currently a director of Valeritas, Inc., ImmunoGen, Inc., the Biotechnology Industry Organization (BIO) and the Greater Philadelphia Life Sciences Congress. She is also an advisor to the Healthcare Businesswoman's Association metro chapter. She has a B.S. and an M.B.A. from the University of Illinois, Champaign-Urbana.
David Stack joined Amarin as a Non-Executive Director in December 2012. Mr. Stack is currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr. Stack has been a managing director of MPM Capital since 2005 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories from 1981 until 1993, in various positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., PepTx, Inc. and Medivo, Inc. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. We believe Mr. Stack's qualifications to sit on our board of directors include his extensive experience with pharmaceutical companies, his financial expertise and his years of experience providing strategic and financial advisory services to pharmaceutical and biotechnology organizations.